ArticleFEMS microbiology reviews2022
Genomics and pathotypes of the many faces of Escherichia coli.
Article in FEMS microbiology reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 124 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
124 citing papers in PubMed, 204 citations in OpenAlex.
- Attenuating ETEC virulence using a heat-labile enterotoxin-blocking binding protein.Gut microbes · 2026Article
- Re-Emerging Bacterial Pathogens, Resistance Genes and Promising Bioindicators in Raw and Treated Sewage-Addressing a Known Issue from a Different Angle and Perspective.Microorganisms · 2026Article
- Performance of the IR Biotyper, Nanopore, and Illumina sequencing to discriminateMicrobiology spectrum · 2026Article
- Gypenosides Mitigate STEC-Induced Intestinal Injury Through Modulation of Ferroptosis Involving the ATF4-CHAC1-GPX4 Axis.Antioxidants (Basel, Switzerland) · 2026Article
- Ribosome-inactivating proteins in bacteria.Microbial genomics · 2026Review
- Genomic characterization of the type VI secretion system in extraintestinal pathogenicMicrobiology spectrum · 2026Article
- Microbiological findings, antibiotic resistance rates and prescription practices for older women with recurrent urinary tract infections: a descriptive study alongside a multinational randomized controlled trial (ImpresU).JAC-antimicrobial resistance · 2026Article
- Genetic control of Group 3 (K96) capsule synthesis and complement resistance in extraintestinal pathogenicmSphere · 2026Article
- Article
- Double agent: how Escherichia coli switches from commensal to pathogen in the urinary tract infection.Infection · 2026Review
- Global Distribution and Comparative Resistance Profiles ofFood science & nutrition · 2026Article
- Curcumin Nanoencapsulated in Chitosan-Coated Liposomes: Therapeutic Potential against PathogenicACS omega · 2026Article
- EcoliTyper: a species-optimized computational pipeline for comprehensive genotyping and surveillance of Escherichia coli.BMC bioinformatics · 2026Article
- Analysis of the genetic and phylogenetic context ofApplied and environmental microbiology · 2026Article
- Prevalence of extended-spectrum β-lactamase and carbapenemase-producing Escherichia coli from patients, cattle, and environmental sources in northwest Amhara, Ethiopia: a one health approach.BMC microbiology · 2026Article
- Antibiofilm Potential and Mechanisms ofMicroorganisms · 2026Article
- New genotyping method for Escherichia coli using RSXC repeat polymorphism and gene-neighborhood architecture.BMC genomics · 2026Article
- Molecular characterization of extended-spectrum β-lactamase (ESBL) and virulent genes in multidrug-resistant Escherichia coli isolated from pharmaceutical and environmental Wastewaters in Dhaka, Bangladesh.Scientific reports · 2026Article
- Engineered Escherichia coli as a microbial cell factory for intracellular protein delivery: strains, vectors, mechanisms, and therapeutic applications.Microbial cell factories · 2026Review
- TheJournal of proteome research · 2026Article
64 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
Escherichia coli is the most researched microbial organism in the world. Its varied impact on human health, consisting of commensalism, gastrointestinal disease, or extraintestinal pathologies, has generated a separation of the species into at least eleven pathotypes (also known as pathovars). These are broadly split into two groups, intestinal pathogenic E. coli (InPEC) and extraintestinal pathogenic E. coli (ExPEC). However, components of E. coli's infinite open accessory genome are horizontally transferred with substantial frequency, creating pathogenic hybrid strains that defy a clear pathotype designation. Here, we take a birds-eye view of the E. coli species, characterizing it from historical, clinical, and genetic perspectives. We examine the wide spectrum of human disease caused by E. coli, the genome content of the bacterium, and its propensity to acquire, exchange, and maintain antibiotic resistance genes and virulence traits. Our portrayal of the species also discusses elements that have shaped its overall population structure and summarizes the current state of vaccine development targeted at the most frequent E. coli pathovars. In our conclusions, we advocate streamlining efforts for clinical reporting of ExPEC, and emphasize the pathogenic potential that exists throughout the entire species.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.